From a therapeutic standpoint, the interaction between liraglutide and GLP-1R is crucial not only for its antidiabetic properties but also for its potential in treating conditions like nonalcoholic steatohepatitis (NASH) and obesity. This evidence concerns the gene GLP1R and obesity disorder.